QF-Pro Home QF-Pro Glossary FLIM-FRET
Technology Hub

FLIM-FRET

The powerful combination of lifetime-based imaging with energy transfer detection–enabling quantitative measurement of protein interactions in clinical tissue samples.

View
Definition
FLIM-FRET combines Fluorescence Lifetime Imaging MicroscopyLoading... with Forster Resonance Energy TransferLoading... detection to provide quantitative, intensity-independent measurement of protein-protein interactions. While FRET detects molecular proximity at 1–10 nm, FLIM's lifetime-based detection ensures measurements remain robust across variable protein expression levels–essential for clinical diagnostics where sample heterogeneity is the norm.
Two Technologies, One Platform
FLIM + FRET synergy
Intensity Independence
Robust to expression variation
Functional Biomarkers
Measure what drugs target
Clinical Translation
QF-Pro + Violet 3.0 workflow

Why Combine FLIM with FRET?

FRETLoading... alone detects molecular proximity at 1–10 nanometers–precisely the distance scale of protein-protein interactions. But traditional intensity-based FRET measurements are confounded by expression variation: high signal could mean high FRET efficiency OR high protein levels.

FLIMLoading... solves this by measuring fluorescence lifetime–an intrinsic property that decreases when FRET occurs. Critically, this lifetime change is independent of how much protein is present. Whether a sample has abundant protein or sparse protein at an immune synapse, the lifetime measurement remains quantitative.

This combination enables detection of biologically decisive interactions that expression-based assays miss–including checkpointLoading... engagement in patients labeled "PD-L1 negative" by conventional testing.

Simplified

The Problem: Traditional fluorescence measurements can't tell whether a bright signal means "lots of interaction" or just "lots of protein."

The Solution: Fluorescence lifetime (FLIM) changes when FRET occurs, but doesn't change based on protein amount. This gives us a true measure of interaction, regardless of expression level.

Clinical Applications

FLIM-FRET enables two categories of functional biomarkersLoading...:

iFRETLoading... (intermolecular FRET) measures interactions between different proteins–such as PD-1/PD-L1Loading... or CTLA-4/CD80Loading... checkpoint engagement. Clinical studies show this predicts immunotherapy response where expression-based testing fails.

aFRETLoading... (amplified FRET) measures conformational changes within single proteins–such as PKB/AktLoading... kinase activation. This detects active signaling pathways regardless of total protein expression.

Both applications share the same insight: measuring function directly predicts drug response better than measuring expression.

Simplified

Two Types of Measurement:

iFRET: Are these two proteins interacting? (e.g., Is PD-1 bound to PD-L1?)

aFRET: Is this protein activated? (e.g., Is the Akt kinase turned on?)

Both predict drug response better than measuring protein levels alone.

Go Deeper

Simplified

Learn more about each technology:

FLIMLoading...: How lifetime imaging works

FRETLoading...: The physics of energy transfer

FRET EfficiencyLoading...: Quantifying the measurement

iFRETLoading...: Clinical checkpoint applications

Expression Measurement
Measure protein levels via IHC or gene expression. Assume higher expression means greater biological activity.
Functional Measurement
Measure protein interactions and activation states directly via FLIM-FRET. Detect biological activity regardless of expression level.

Published Clinical Evidence

  • PD-1/PD-L1 interaction: Predicted NSCLC survival (P<0.0001) while expression did not (P=0.162)
  • PKB/Akt activation: Predicted ccRCC survival (HR=0.228, P=0.002) while expression did not
  • CTLA-4/CD80 + PD-1/PD-L1: Combined interaction biomarker identified "double high" patients with 35-month median OS

Connected Terms

Share This Term
Term Connections